L-type prostaglandin synthase (L-PGDS) produces PGDProstaglandins (PGs) 5 are lipid mediators formed from arachidonic acid through the action of cyclooxygenases (COXs). COXs convert arachidonic acid released from the plasma membrane to an intermediate substrate, PGH 2 , which is metabolized by specific synthases to produce PGs like PGD 2 (1, 2). PGD 2 is involved in various physiological processes such as vasodilatation, bronchoconstriction (3), regulation of pain (4), and sleep (5) but is also implicated in inflammatory responses such as asthma (6) and atherosclerosis (7). PGD 2 was shown to exhibit anti-inflammatory properties as well, as increased levels of PGD 2 are observed during the resolution phase of inflammation (8 -10). Recent work by our group showed that PGD 2 displays anabolic properties in bone (11,12).There are two types of prostaglandin D 2 synthase (PGDS). The hematopoietic PGDS (H-PGDS) is glutathione-requiring (13) and is expressed mainly in mast cells (14), megakaryocytes (15), and T-helper 2 lymphocytes (16). The lipocalintype PGDS (L-PGDS), also called -trace, is glutathione-independent and is expressed abundantly in the central nervous system (17, 18), the heart (19), the retina (20), and the genital organs (21). L-PGDS is also the only enzyme among the members of the lipocalin gene family and binds small lipophilic substances like retinoic acid (22), bilirubin (23), and gangliosides (24).The arrestin family consists of ubiquitously expressed arrestin-2 and -3 (also known as -arrestin-1 and -2) and two retinal arrestins (25). Arrestin-2 and -3 are multifunctional molecules in addition to their well known role in desensitization and internalization of G protein-coupled receptors (26). The identification of numerous non-receptor binding partners has expanded their functions to protein ubiquitination, chemotaxis, apoptosis, mitogen-activated protein kinases activation (27, 28), osteoclastogenesis inhibition (29), and regulation of the interleukin 1 (IL-1) pathway (30).It is remarkable how very little is known about the interaction partners and the mechanisms regulating the activity of PG synthases considering their crucial physiological and pathological roles and the clinical problems associated with the long term use of COX inhibitors. Here we show that arrestin-3 interacts with L-PGDS and increases L-PGDS-mediated PGD 2 production. An arrestin-3 peptide was identified as capable of inducing PGD 2 production by L-PGDS. This is important because it shows that by identifying interacting partners of PG synthases we can not only further our understanding of the